Navigation Links
Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
Date:6/12/2008

CALGARY, June 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), announced today that Dr. Brad Thompson, President and CEO of Oncolytics, will participate in two separate presentations at the BIO 2008 International Convention.

Dr. Thompson is scheduled to provide a corporate overview of the Company on Tuesday, June 17th at 3:30 p.m. PT at the BIO Business Forum.

On Wednesday, June 18th at 4:00 p.m. PT, Dr. Thompson is also scheduled to participate as an invited speaker as part of a panel discussion entitled "Canada: Your Global Partner for Cancer Research Innovation."

The Conference, which is expected to draw approximately 20,000 attendees, will be held at the San Diego Convention Center June 17th to June 20th, 2008.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation times are subject to change. This release and the presentations related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pha
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... 29, 2014 Eppendorf Centrifuge 5427 ... selection. Eppendorf 5427 R is geared towards high-end applications ... it is targeted towards work requiring high sample throughput. ... as it compliments their extensive 16, 48, and 64 ... microcentrifuge tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... energy company, BioPower Systems (BPS), today announced that the ... O,Brien MP, has awarded the company conditional funding support ... Program. The funding will be applied towards ... bioWAVE ocean wave energy system at a grid-connected site ...
... Medical Center researchers could still be close to giving heart ... The "LateTIME" trial was a study of adult ... to have the ability to improve heart function after an ... the attack. Results were released this week ...
... Palatin Technologies, Inc. (NYSE Amex: ... peptide therapeutics for the treatment of diseases with ... announced that Dr. Carl Spana, President and Chief ... Area Partnerships conference on Thursday, December 1, 2011.  ...
Cached Biology Technology:BioPower Systems Awarded $5 Million from Victorian Government 2BioPower Systems Awarded $5 Million from Victorian Government 3Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise 2Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference 2
(Date:7/29/2014)... in locomotion. Swimming microorganisms, such as bacteria and spermatozoa, ... the viscous forces exerted by the surrounding fluid. ... scientists have found that the direction of propulsion made ... by a viscoelastic fluid. These findings have been published ... the Alternative Energies and Atomic Energy Commission (CEA), in ...
(Date:7/29/2014)... wildfires that have been plaguing the Northern Territories in ... Great Lakes in the U.S. continue on. NASA,s ... Resolution Imaging Spectroradiometer, MODIS, instrument on July 26, 2014. ... outlined in red. Copious amount of smoke are drifting ... havoc for residents of Yellowknife. Fire has caused ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
Breaking Biology News(10 mins):Optimum inertial self-propulsion design for snowman-like nanorobot 2
... GOCE satellite from the Plesetsk cosmodrome in northern Russia had ... due to an anomaly identified in one of the units ... stage (Breeze KM ). The correction of the problem ... perform this operation, it will be necessary to de-mate the ...
... physician-geneticist and leader of the Human Genome Project, has ... the Inamori International Center for Ethics and Excellence at ... and Kyoto Prizes for science, technology, philosophy and the ... ethical leaders. It is presented annually to an individual ...
... de los Alimentos (Institute of Nutrition and Food Technology) ... doing research into the positive effects of Mediterranean diet,s ... is a new research line about pancreatic cancer cells. ... points out that in the study ,Influence of the ...
Cached Biology News:Leader of Human Genome Project honored with the Inamori Ethics Prize 2New studies on the Mediterranean diet confirm its effectiveness for chronic disease prevention 2
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
... and reproducible immunoprecipitation (IP) by using a 96 ... than regular IPs, which are problematic with regards ... the agarose bed. The binding of the antibody/antigen ... elution of the immune complex can occur with ...
... The Yeast Oligo Microarray Kit (V2), ... to simultaneously characterize expression of many ... gene activity during important biological processes. ... representing 6,256 known ORFs from the ...
Biology Products: